Cognition Theraputics Inc.
Cognition Theraputics Inc. is listed today as Cognition Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
7 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $2 M | No. 7 | Under $2 million | debt, options | SEC | |
| Mar 2018 | $2 M | No. 6 | $2 to $10 million | debt, options | SEC | |
| Nov 2016 | $4 M | No. 5 | $2 to $10 million | equity | SEC | |
| Mar 2016 | $3 M | No. 4 | $2 to $10 million | debt, options | SEC | |
| Mar 2014 | $16 M | No. 3 | $10 to $50 million | equity | SEC | |
| Dec 2011 | $2 M | No. 2 | Under $2 million | equity | SEC | |
| Dec 2010 | $3 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cognition Theraputics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).
SEC Form D · Nov 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2018
That is all the official record says: Cognition Theraputics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cognition Theraputics Inc. are on record.
Investors#
19 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| BIOS Advisors GP, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Capital Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Equity Partners III, LP | Private equity | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Bios Equity Partners II, LP | Private equity | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Bios Equity Partners, LP | Private equity | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund III, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund III NT, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund III QP, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund II, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund II NT, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund II QP, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund I, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Fund I QP, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Memory SPV II, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| BIOS Memory SPV I, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Cavu Advisors, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Cavu Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Golden Seeds Cognition Therapeutics LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Ogden CAP Associates, LLC | Other | not stated | not stated | Held Series A, A-1, A-2, B and B-1 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 56 investors.
Largest shareholders today
Institutions holding Cognition Therapeutics, Inc. shares, as of Sep 30, 2026.
- BIOS Capital Management, LP$6 M6.31%
- DAVENPORT & Co LLC$4 M4.47%
- Vanguard Capital Management LLC$3 M3.62%
- BlackRock, Inc.$1 M1.32%
- Chescapmanager LLC$1 M1.05%
- Geode Capital Management, LLC$1 M0.96%
- Renaissance Technologies LLC$1 M0.62%
- Hilton Capital Management, LLC$1 M0.58%
- Vanguard Fiduciary Trust Co$0 M0.53%
- CM Management, LLC$0 M0.45%
- Sigma Planning Corp$0 M0.38%
- State Street Corp$0 M0.37%
- Tocqueville Asset Management L.P.$0 M0.24%
- Dauntless Investment Group, LLC$0 M0.22%
- American Financial Group Inc$0 M0.22%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kenneth I. Moch | Executive officer | Nov 2018 |
| Susan I. Catalano | Executive officer | Nov 2018 |
| Kenneth Moch | Executive officer | Jan 2017 |
| Susan Catalano | Executive officer | Jan 2017 |
| Harold Safferstein | Executive officer | Mar 2016 |
| Harold T. Safferstein | Executive officer | Dec 2011 |
| Aaron I. Fletcher | Director | Nov 2018 |
| Irwin I. Scher | Director | Nov 2018 |
| Kenneth I. Moch | Director | Nov 2018 |
| Mark I. Breedlove | Director | Nov 2018 |
| Peggy I. Wallace | Director | Nov 2018 |
| Robert I. Gailus | Director | Nov 2018 |
| Stephen I. Sands | Director | Nov 2018 |
| Susan I. Catalano | Director | Nov 2018 |
| Aaron Fletcher | Director | Jan 2017 |
| Irwin Scher | Director | Jan 2017 |
| Kenneth Moch | Director | Jan 2017 |
| Mark Breedlove | Director | Jan 2017 |
| Peggy Wallace | Director | Jan 2017 |
| Robert Gailus | Director | Jan 2017 |
| Susan Catalano | Director | Jan 2017 |
| Franz Hefti | Director | Nov 2016 |
| Harold Safferstein | Director | Mar 2016 |
| Nada Jain | Director | Mar 2016 |
| Franz T. Hefti | Director | Dec 2011 |
| Harold T. Safferstein | Director | Dec 2011 |
| Mark T. Breedlove | Director | Dec 2011 |
| Nada T. Jain | Director | Dec 2011 |
| Robert T. Gailus | Director | Dec 2011 |
| Franz F. Hefti | Director | Dec 2010 |
| Mark F. Breedlove | Director | Dec 2010 |
| Nada F. Jain | Director | Dec 2010 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.